Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care

IF 3.3 3区 医学 Q2 ONCOLOGY Clinical lung cancer Pub Date : 2024-08-31 DOI:10.1016/j.cllc.2024.08.011
Christopher M. Kapp, Chelsi Green, Jeffrey Thiboutot, Jeremy Kim, Mary M. Pasquinelli, Benjamin Aronson, A. Christine Argento
{"title":"Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care","authors":"Christopher M. Kapp, Chelsi Green, Jeffrey Thiboutot, Jeremy Kim, Mary M. Pasquinelli, Benjamin Aronson, A. Christine Argento","doi":"10.1016/j.cllc.2024.08.011","DOIUrl":null,"url":null,"abstract":"Lung cancer remains the leading cause of cancer death in the United States. There is an association between certain social determinants of health (SDOH) and adverse cancer outcomes. These include Black race and low-income, which are associated with poorer adherence to lung cancer screening and presentation at a later stage of disease. We conducted a retrospective review of all patients with a diagnosis of lung cancer at a single urban, academic center from 2015 to 2021. Demographic data including race and clinical data including time taken to progress through various checkpoints (ie, concerning CT scan to diagnosis, diagnosis to treatment) were collected. Income data was approximated based on population medians at patient's home address zip code. A total of 550 patients were included in the final analysis. The study population was 57.4% Black and 61.2% of patients presenting with a household income of $40,000 US Dollars or lower based on approximated median household income. The time from CT scan to first treatment for the entire cohort was 121.3 days with no statistically significant variance by race. However, among patients presenting at stage IV, 72.7% were black and 76.0% resided in a zip code with a median income < $40,000. This study demonstrated no significant delays in progressing through checkpoints of lung cancer diagnosis and treatment on the basis of race or income approximation. Black patients and patients in low-income households were diagnosed with lung cancer at a more advanced stage. Efforts to close the gap in lung cancer disparities should be focused on targeting screening and early identification toward social groups that may be at highest risk of late presentation. Institutional focus on patient navigation through these stages should be paramount. There were no delays in progression to lung cancer diagnostic and therapeutic milestones based on race or income approximation.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2024.08.011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer remains the leading cause of cancer death in the United States. There is an association between certain social determinants of health (SDOH) and adverse cancer outcomes. These include Black race and low-income, which are associated with poorer adherence to lung cancer screening and presentation at a later stage of disease. We conducted a retrospective review of all patients with a diagnosis of lung cancer at a single urban, academic center from 2015 to 2021. Demographic data including race and clinical data including time taken to progress through various checkpoints (ie, concerning CT scan to diagnosis, diagnosis to treatment) were collected. Income data was approximated based on population medians at patient's home address zip code. A total of 550 patients were included in the final analysis. The study population was 57.4% Black and 61.2% of patients presenting with a household income of $40,000 US Dollars or lower based on approximated median household income. The time from CT scan to first treatment for the entire cohort was 121.3 days with no statistically significant variance by race. However, among patients presenting at stage IV, 72.7% were black and 76.0% resided in a zip code with a median income < $40,000. This study demonstrated no significant delays in progressing through checkpoints of lung cancer diagnosis and treatment on the basis of race or income approximation. Black patients and patients in low-income households were diagnosed with lung cancer at a more advanced stage. Efforts to close the gap in lung cancer disparities should be focused on targeting screening and early identification toward social groups that may be at highest risk of late presentation. Institutional focus on patient navigation through these stages should be paramount. There were no delays in progression to lung cancer diagnostic and therapeutic milestones based on race or income approximation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解阻碍公平肺癌治疗的社会风险因素
肺癌仍然是美国癌症死亡的主要原因。某些健康的社会决定因素(SDOH)与癌症的不良后果之间存在关联。这些因素包括黑人种族和低收入,这与较差的肺癌筛查依从性和较晚的发病阶段有关。我们对 2015 年至 2021 年期间在一个城市学术中心确诊为肺癌的所有患者进行了回顾性研究。我们收集了包括种族在内的人口统计学数据和包括通过不同检查点(即从 CT 扫描到诊断、从诊断到治疗)所需时间在内的临床数据。收入数据是根据患者家庭住址邮政编码的人口中位数估算的。共有 550 名患者被纳入最终分析。研究人群中 57.4% 为黑人,61.2% 的患者家庭收入在 40,000 美元或以下(根据家庭收入中位数估算)。整个组群从 CT 扫描到首次治疗的时间为 121.3 天,不同种族的差异无统计学意义。不过,在 IV 期患者中,72.7% 是黑人,76.0% 居住在收入中位数低于 4 万美元的邮编区。这项研究表明,在肺癌诊断和治疗的检查点上,并没有因种族或收入近似而出现明显的延误。黑人患者和低收入家庭患者被诊断出肺癌时已是晚期。缩小肺癌差异的努力应集中在针对晚期发病风险最高的社会群体进行筛查和早期识别。在这些阶段中,机构对患者指导的重视应该是最重要的。在肺癌诊断和治疗的阶段性进展方面,没有出现因种族或收入近似而导致的延误。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical lung cancer
Clinical lung cancer 医学-肿瘤学
CiteScore
7.00
自引率
2.80%
发文量
159
审稿时长
24 days
期刊介绍: Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
期刊最新文献
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care Response to Editor: Commentary on “Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma” Letter to the Editor in Response to “Adherence to Annual Lung Cancer Screening in a Centralized Academic Program”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1